食管癌新辅助每日两次放化疗:治疗相关死亡与长期结局
研究分析250例可切除食管癌患者接受术前超分割加速放化疗(45 Gy,30次,每日两次,3周)后行计划性经裂孔食管切除术的结局。围手术期死亡率为4%,全组中位OS为28.4个月,手术患者为35.1个月,3年局部区域控制率为83%。
要点
- 术前超分割加速放化疗(45 Gy/30次/每日两次/3周)联合手术的围手术期死亡率为4%。
- 全组中位OS为28.4个月,手术患者中位OS为35.1个月,3年局部区域控制率为83%。
- 独立病理复核的129例中29%达完全缓解,该组中位OS为98.9个月、3年OS为74%。
核心结论
- 食管癌新辅助每日两次放化疗是安全有效的每日一次分割替代方案,治疗相关死亡率低,长期结局与标准分割疗程相似。
研究设计与样本
- 分析250例连续的可切除食管癌患者,接受术前超分割加速放化疗(45 Gy,30次,每日两次,3周)后行计划性经裂孔食管切除术。
主要发现
- 存活患者中位随访59个月,87%为腺癌、13%为鳞状细胞癌。
- 223例手术患者中10例在3个月内死亡,围手术期死亡率为4%。
- 全组中位OS为28.4个月(95%CI 22.3-35.6个月),手术患者中位OS为35.1个月(95%CI 27.4-47个月)。
- 孤立局部区域失败32例,3年局部区域控制率为83%;独立病理复核的129例中29%达完全缓解,该组中位OS为98.9个月、3年OS为74%。
临床怎么用
- 可考虑将新辅助每日两次放化疗作为可切除食管癌的术前方案,需关注围手术期死亡率为4%及术后病理完全缓解对长期生存的提示意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Because of the short potential doubling time of esophageal cancer, there is a theoretical benefit to using an accelerated radiation treatment schedule. This study evaluates outcomes and treatment-related mortality and morbidity of patients treated with neoadjuvant hyperfractionated accelerated chemoradiation for resectable esophageal cancer. METHODS AND MATERIALS: Outcomes from 250 consecutive patients with resectable esophageal cancer treated with preoperative hyperfractionated accelerated chemoradiotherapy (45 Gy in 30 twice-daily fractions over 3 weeks) followed by planned transhiatal esophagectomy were analyzed. Grade 3 or greater treatment related toxicity, surgical complications, and treatment-related mortality were determined. Additionally, available surgical specimens were graded for pathological response to chemoradiation. Overall survival (OS) and locoregional control were calculated using the Kaplan-Meier method. The log rank test was used to determine statistical significance. RESULTS: Median follow-up was 59 months for surviving patients; 87% of patients had adenocarcinoma and 13% had squamous cell carcinoma. Eleven percent of patients did not have surgery because of the development of metastases, declining performance status, or refusal. Twenty-seven patients were found to have unresectable and/or metastatic disease at the time of surgery. Overall, 10 of 223 operated patients died within 3 months, resulting in a perioperative mortality rate of 4%. Median OS was 28.4 months (95% confidence interval, 22.3-35.6 months) for all patients and 35.1 months (95% confidence interval, 27.4-47 months) for patients who underwent esophagectomy. There were 32 isolated locoregional failures with a 3-year locoregional control rate of 83%. Of 129 patients who had independent pathology review, 29% had complete response to treatment. This group had a median OS of 98.9 months and 3-year OS of 74%. CONCLUSION: Neoadjuvant twice-daily chemoradiation for esophageal cancer is a safe and effective alternative to daily fractionation with low treatment-related mortality and long-term outcomes similar to standard fractionation courses.
引用
- Samuels SE, Stenmark MH, Lee JY, et al. Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. Adv Radiat Oncol. 2017. PMID: 29114597. doi:10.1016/j.adro.2017.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。